Pelthos Therapeutics Signs Major Pharmacy Benefit Manager Agreement Expanding Patient Access to ZELSUVMI™ (berdazimer) Topical Gel, 10.3%

Core Insights - Pelthos Therapeutics has launched ZELSUVMI, the first FDA-approved at-home treatment for molluscum contagiosum, a viral skin condition affecting approximately 16.7 million people in the U.S. with 6 million new cases annually [1][5] Company Developments - Pelthos has signed its first commercial agreement with a Group Purchasing Organization to enhance patient access to ZELSUVMI, which began formulary inclusion updates on December 1, 2025 [2] - The CEO of Pelthos, Scott Plesha, emphasized that this partnership with a national pharmacy benefit manager is a significant milestone for increasing commercial coverage and improving access for patients seeking at-home treatment [3] - The Chief Commercial Officer, Sai Rangarao, stated that the PBM partnership aligns with the company's commitment to reducing barriers for patients and enhancing access to ZELSUVMI [4] Product Information - ZELSUVMI is a topical nitric oxide-releasing gel indicated for the treatment of molluscum contagiosum in adults and pediatric patients aged one year and older, launched in July 2025 [3][6] - The product is designed for convenient at-home application and is effective for treating infections in sensitive areas of the body [3][6] - ZELSUVMI received a Novel Drug designation from the FDA in January 2024, marking it as the first and only prescription therapy approved for at-home use [1][6] Industry Context - Molluscum contagiosum is a highly contagious viral skin infection, particularly prevalent among children, with a significant portion of cases going untreated [5] - The condition can lead to discomfort and social stigma, with 30% of children experiencing lesions that persist beyond 18 months [5]